| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Venlafaxine is a structurally novel, nontricyclic compound that is being evaluated for the treatment of various depressive disorders. A randomized three-period crossover study was conducted to obtain pharmacokinetic and dose proportionality data on the drug and its active metabolite, O-desmethylvenlafaxine. Eighteen healthy young men received single doses of venlafaxine 25, 75, and 150 mg followed by 3 days of administration every 8 hours (q8h). Steady-state elimination half-life was 3 to 4 hours for venlafaxine and 10 hours for O-desmethylvenlafaxine; both were independent of dose. Venlafaxine had a high oral-dose clearance, ranging from 0.58 to 2.63 L/hr/kg across doses with the lowest mean clearance, 0.98 L/hr/kg, at the highest dose. The apparent clearance of O-desmethylvenlafaxine was lower than venlafaxine, ranging from 0.21 to 0.66 L/hr/kg, and the lowest mean clearance, 0.33 L/hr/kg, occurred at the lowest dose. The area under the metabolite curve was two to three times greater than that for venlafaxine. Each compound had linear dose proportionality up to 75 mg q8h. A composite parameter incorporating venlafaxine plus O-desmethylvenlafaxine was introduced (i.e., AUC [area under the curve] + activity factor.AUCm), which extended linearity to 150 mg q8h. In summary, venlafaxine is a high-clearance drug that forms a metabolite with almost equal activity and demonstrates linear dose-proportionality.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  C. C. Crone, G. M. Gabriel, and A. DiMartini An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist Psychosomatics, June 1, 2006; 47(3): 188 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Mahmood, M. D. Green, and J. E. Fisher Selection of the First-Time Dose in Humans: Comparison of Different Approaches Based on Interspecies Scaling of Clearance J. Clin. Pharmacol., July 1, 2003; 43(7): 692 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gonzalez-Pinto, M. Gutierrez, N. Gonzalez, E. Elizagarate, J. L. Perez de Heredia, and J. A. Mico Efficacy and Safety of Venlafaxine-ECT Combination in Treatment-Resistant Depression J Neuropsychiatry Clin Neurosci, May 1, 2002; 14(2): 206 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Harvey, R. L. Rudolph, and S. H. Preskorn Evidence of the Dual Mechanisms of Action of Venlafaxine Arch Gen Psychiatry, May 1, 2000; 57(5): 503 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Khalifa, P. Daleau, and a. J. Turgeon Mechanism of Sodium Channel Block by Venlafaxine in Guinea Pig Ventricular Myocytes J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 280 - 284. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Blythe and L P. Hackett Cardiovascular and neurological toxicity of venlafaxine Human and Experimental Toxicology, May 1, 1999; 18(5): 309 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 D. R. Taft, G. R. Iyer, L. Behar, and R. V. Digregorio Application of a First-Pass Effect Model to Characterize the Pharmacokinetic Disposition of Venlafaxine after Oral Administration to Human Subjects Drug Metab. Dispos., October 1, 1997; 25(10): 1215 - 1218. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Goldberg The P-450 System: Definition and Relevance to the Use of Antidepressants in Medical Practice Arch Fam Med, July 1, 1996; 5(7): 406 - 412. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
